Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer: a systematic review

Programmed cell death ligand 1 (PD‐L1) immunohistochemistry is used to determine which patients with advanced non‐small‐cell lung cancer (NSCLC) respond best to treatment with PD‐L1 inhibitors. For each inhibitor, a unique immunohistochemical assay was developed. This systematic review gives an up‐t...

Descripción completa

Detalles Bibliográficos
Autores principales: Koomen, Bregje M, Badrising, Sushil K, van den Heuvel, Michel M, Willems, Stefan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318295/
https://www.ncbi.nlm.nih.gov/pubmed/31793055
http://dx.doi.org/10.1111/his.14040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318295/
https://www.ncbi.nlm.nih.gov/pubmed/31793055
http://dx.doi.org/10.1111/his.14040

Ejemplares similares